Literature DB >> 27600282

Expression patterns of the activator protein-1 (AP-1) family members in lymphoid neoplasms.

Alexandra Papoudou-Bai1, Eleftheria Hatzimichael2, Alexandra Barbouti3, Panagiotis Kanavaros4.   

Abstract

The activator protein-1 (AP-1) is a dimeric transcription factor composed of proteins belonging to the Jun (c-Jun, JunB and JunD), Fos (c-Fos, FosB, Fra1 and Fra2) and activating transcription factor protein families. AP-1 is involved in various cellular events including differentiation, proliferation, survival and apoptosis. Deregulated expression of AP-1 transcription factors is implicated in the pathogenesis of various lymphomas such as classical Hodgkin lymphomas, anaplastic large cell lymphomas, diffuse large B cell lymphomas and adult T cell leukemia/lymphoma. The main purpose of this review is the analysis of the expression patterns of AP-1 transcription factors in order to gain insight into the histophysiology of lymphoid tissues and the pathology of lymphoid malignancies.

Entities:  

Keywords:  AP-1; Lymphoid tissues; Lymphomas

Mesh:

Substances:

Year:  2016        PMID: 27600282     DOI: 10.1007/s10238-016-0436-z

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  127 in total

Review 1.  Chemokines and chemokine receptors: their manifold roles in homeostasis and disease.

Authors:  Yingying Le; Ye Zhou; Pablo Iribarren; Jiming Wang
Journal:  Cell Mol Immunol       Date:  2004-04       Impact factor: 11.530

2.  Hypomethylation of CD30 CpG islands with aberrant JunB expression drives CD30 induction in Hodgkin lymphoma and anaplastic large cell lymphoma.

Authors:  Mariko Watanabe; Yuji Ogawa; Kinji Itoh; Tukasa Koiwa; Marshall E Kadin; Toshiki Watanabe; Isao Okayasu; Masaaki Higashihara; Ryouichi Horie
Journal:  Lab Invest       Date:  2007-10-29       Impact factor: 5.662

3.  JunB breakdown in mid-/late G2 is required for down-regulation of cyclin A2 levels and proper mitosis.

Authors:  Rosa Farràs; Véronique Baldin; Sandra Gallach; Claire Acquaviva; Guillaume Bossis; Isabelle Jariel-Encontre; Marc Piechaczyk
Journal:  Mol Cell Biol       Date:  2008-04-07       Impact factor: 4.272

4.  c-JUN N-terminal kinase (JNK) is activated and contributes to tumor cell proliferation in classical Hodgkin lymphoma.

Authors:  Vasiliki Leventaki; Elias Drakos; Maria Karanikou; Konstantina Psatha; Pei Lin; Ellen Schlette; Aris Eliopoulos; Theodoros P Vassilakopoulos; Helen Papadaki; Efstratios Patsouris; L Jeffrey Medeiros; George Z Rassidakis
Journal:  Hum Pathol       Date:  2013-10-31       Impact factor: 3.466

Review 5.  Anaplastic large cell lymphoma, ALK-positive.

Authors:  Andrés J M Ferreri; Silvia Govi; Stefano A Pileri; Kerry J Savage
Journal:  Crit Rev Oncol Hematol       Date:  2012-03-21       Impact factor: 6.312

6.  The oncogenic JUNB/CD30 axis contributes to cell cycle deregulation in ALK+ anaplastic large cell lymphoma.

Authors:  Vassilis Atsaves; Lazaros Lekakis; Elias Drakos; Vasiliki Leventaki; Mehran Ghaderi; George E Baltatzis; Dimitris Chioureas; Dan Jones; Marianna Feretzaki; Chryssoula Liakou; Panayiotis Panayiotidis; Vassilis Gorgoulis; Efstratios Patsouris; L Jeffrey Medeiros; Francois X Claret; George Z Rassidakis
Journal:  Br J Haematol       Date:  2014-08-22       Impact factor: 6.998

Review 7.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors:  Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

8.  Expression of cyclin D3 and cyclin E and identification of distinct clusters of proliferation and apoptosis in diffuse large B-cell lymphomas.

Authors:  M Bai; E Tsanou; N J Agnantis; A Chaidos; D Dimou; A Skyrlas; S Dimou; M Vlychou; V Galani; P Kanavaros
Journal:  Histol Histopathol       Date:  2003-04       Impact factor: 2.303

9.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

Authors:  Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

10.  Aberrant expression of Fra-2 promotes CCR4 expression and cell proliferation in adult T-cell leukemia.

Authors:  T Nakayama; K Hieshima; T Arao; Z Jin; D Nagakubo; A-K Shirakawa; Y Yamada; M Fujii; N Oiso; A Kawada; K Nishio; O Yoshie
Journal:  Oncogene       Date:  2007-12-10       Impact factor: 9.867

View more
  18 in total

1.  Apolipoprotein D as a Potential Biomarker and Construction of a Transcriptional Regulatory-Immune Network Associated with Osteoarthritis by Weighted Gene Coexpression Network Analysis.

Authors:  Yong Qin; Jia Li; Yonggang Zhou; Chengliang Yin; Yi Li; Ming Chen; Yinqiao Du; Tiejian Li; Jinglong Yan
Journal:  Cartilage       Date:  2021-10-31       Impact factor: 3.117

2.  Cloning and expression of a transcription factor activator protein-1 member identified from the swimming crab Portunus trituberculatus.

Authors:  Huan Wang; Ce Shi; Mengyao Kong; Changkao Mu; Hongling Wei; Chunlin Wang
Journal:  Cell Stress Chaperones       Date:  2018-09-25       Impact factor: 3.667

3.  Comparative Transcriptomic Analysis of the Hematopoietic System between Human and Mouse by Single Cell RNA Sequencing.

Authors:  Shouguo Gao; Zhijie Wu; Jeerthi Kannan; Liza Mathews; Xingmin Feng; Sachiko Kajigaya; Neal S Young
Journal:  Cells       Date:  2021-04-21       Impact factor: 6.600

4.  Galectin-1 knockdown improves drug sensitivity of breast cancer by reducing P-glycoprotein expression through inhibiting the Raf-1/AP-1 signaling pathway.

Authors:  Fang Wang; Pengwei Lv; Yuanting Gu; Lin Li; Xin Ge; Guangcheng Guo
Journal:  Oncotarget       Date:  2017-04-11

5.  Methyl-dependent and spatial-specific DNA recognition by the orthologous transcription factors human AP-1 and Epstein-Barr virus Zta.

Authors:  Samuel Hong; Dongxue Wang; John R Horton; Xing Zhang; Samuel H Speck; Robert M Blumenthal; Xiaodong Cheng
Journal:  Nucleic Acids Res       Date:  2017-03-17       Impact factor: 16.971

6.  c-Jun Proto-Oncoprotein Plays a Protective Role in Lung Epithelial Cells Exposed to Staphylococcal α-Toxin.

Authors:  Alejandro J Moyano; Ana C Racca; Gastón Soria; Héctor A Saka; Verónica Andreoli; Andrea M Smania; Claudia Sola; José L Bocco
Journal:  Front Cell Infect Microbiol       Date:  2018-05-25       Impact factor: 5.293

7.  Distinct abdominal and gluteal adipose tissue transcriptome signatures are altered by exercise training in African women with obesity.

Authors:  Pamela A Nono Nankam; Matthias Blüher; Stephanie Kehr; Nora Klöting; Knut Krohn; Kevin Adams; Peter F Stadler; Amy E Mendham; Julia H Goedecke
Journal:  Sci Rep       Date:  2020-06-24       Impact factor: 4.379

8.  Inhibition of ERKs/Akt-Mediated c-Fos Expression Is Required for Piperlongumine-Induced Cyclin D1 Downregulation and Tumor Suppression in Colorectal Cancer Cells.

Authors:  Feng Gao; Li Zhou; Ming Li; Wenbin Liu; Shuting Yang; Wei Li
Journal:  Onco Targets Ther       Date:  2020-06-15       Impact factor: 4.147

9.  Estrogen Protects Neurotransmission Transcriptome During Status Epilepticus.

Authors:  Dumitru A Iacobas; Sanda Iacobas; Nino Nebieridze; Libor Velíšek; Jana Velíšková
Journal:  Front Neurosci       Date:  2018-06-20       Impact factor: 4.677

10.  Beta-Defensin 2 and 3 Promote Bacterial Clearance of Pseudomonas aeruginosa by Inhibiting Macrophage Autophagy through Downregulation of Early Growth Response Gene-1 and c-FOS.

Authors:  Yongjian Wu; Dandan Li; Yi Wang; Xi Liu; Yuanqing Zhang; Wenting Qu; Kang Chen; Ngiambudulu M Francisco; Lianqiang Feng; Xi Huang; Minhao Wu
Journal:  Front Immunol       Date:  2018-02-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.